MXPA01012355A - Composiciones de peptido a-beta y proceso para producir el mismo. - Google Patents
Composiciones de peptido a-beta y proceso para producir el mismo.Info
- Publication number
- MXPA01012355A MXPA01012355A MXPA01012355A MXPA01012355A MXPA01012355A MX PA01012355 A MXPA01012355 A MX PA01012355A MX PA01012355 A MXPA01012355 A MX PA01012355A MX PA01012355 A MXPA01012355 A MX PA01012355A MX PA01012355 A MXPA01012355 A MX PA01012355A
- Authority
- MX
- Mexico
- Prior art keywords
- compositions
- processes
- producing same
- beta peptide
- abeta peptide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Marine Sciences & Fisheries (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13704799P | 1999-06-01 | 1999-06-01 | |
PCT/US2000/015302 WO2000072870A1 (en) | 1999-06-01 | 2000-06-01 | Compositions of a-beta peptide and processes for producing same |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA01012355A true MXPA01012355A (es) | 2003-06-24 |
Family
ID=22475602
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA01012355A MXPA01012355A (es) | 1999-06-01 | 2000-06-01 | Composiciones de peptido a-beta y proceso para producir el mismo. |
Country Status (25)
Country | Link |
---|---|
EP (1) | EP1181040A1 (no) |
JP (1) | JP2003519620A (no) |
KR (1) | KR20020016813A (no) |
CN (1) | CN1353615A (no) |
AR (1) | AR024558A1 (no) |
AU (1) | AU5726100A (no) |
BG (1) | BG106249A (no) |
BR (1) | BR0011251A (no) |
CA (1) | CA2374897A1 (no) |
CZ (1) | CZ20014150A3 (no) |
EE (1) | EE200100649A (no) |
HK (1) | HK1045938A1 (no) |
HR (1) | HRP20010901A2 (no) |
IL (1) | IL146575A0 (no) |
IS (1) | IS6182A (no) |
MX (1) | MXPA01012355A (no) |
NO (1) | NO20015859L (no) |
NZ (1) | NZ515744A (no) |
PE (1) | PE20010212A1 (no) |
PL (1) | PL352575A1 (no) |
RU (1) | RU2001135800A (no) |
SK (1) | SK17012001A3 (no) |
TR (1) | TR200103476T2 (no) |
WO (1) | WO2000072870A1 (no) |
ZA (1) | ZA200109704B (no) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6750324B1 (en) | 1997-12-02 | 2004-06-15 | Neuralab Limited | Humanized and chimeric N-terminal amyloid beta-antibodies |
US6743427B1 (en) | 1997-12-02 | 2004-06-01 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
US20080050367A1 (en) | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
US6761888B1 (en) | 2000-05-26 | 2004-07-13 | Neuralab Limited | Passive immunization treatment of Alzheimer's disease |
TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
US7790856B2 (en) | 1998-04-07 | 2010-09-07 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
US6787523B1 (en) | 1997-12-02 | 2004-09-07 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
US20030147882A1 (en) | 1998-05-21 | 2003-08-07 | Alan Solomon | Methods for amyloid removal using anti-amyloid antibodies |
US6787637B1 (en) | 1999-05-28 | 2004-09-07 | Neuralab Limited | N-Terminal amyloid-β antibodies |
UA81216C2 (en) | 1999-06-01 | 2007-12-25 | Prevention and treatment of amyloid disease | |
AU2001268005A1 (en) | 2000-07-07 | 2002-01-21 | Lars Lannfelt | Prevention and treatment of alzheimer's disease |
AU1225702A (en) * | 2000-09-19 | 2002-04-02 | Evotec Neurosciences Gmbh | Methods and compounds for treating brain amyloidosis |
US7700751B2 (en) | 2000-12-06 | 2010-04-20 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize β-amyloid peptide |
MY144532A (en) | 2001-08-20 | 2011-09-30 | Lundbeck & Co As H | Novel method for down-regulation of amyloid |
MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
PE20050627A1 (es) | 2003-05-30 | 2005-08-10 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido beta amiloideo |
SE0401601D0 (sv) | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
US8916165B2 (en) | 2004-12-15 | 2014-12-23 | Janssen Alzheimer Immunotherapy | Humanized Aβ antibodies for use in improving cognition |
KR20140087058A (ko) | 2005-11-30 | 2014-07-08 | 애브비 인코포레이티드 | 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도 |
PT2289909E (pt) | 2005-11-30 | 2015-02-10 | Abbvie Inc | Método de rastreio, processo de purificação de globulómeros a-beta não difundíveis, anticorpos selectivos contra os referidos globulómeros a-beta não difundíveis e processo para o fabrico dos referidos anticorpos |
RU2429244C2 (ru) | 2006-03-23 | 2011-09-20 | Байоарктик Ньюросайенс Аб | Улучшенные селективные в отношении протофибрилл антитела и их применение |
WO2009017467A1 (en) | 2007-07-27 | 2009-02-05 | Elan Pharma International Limited | Treatment of amyloidogenic diseases |
US8784810B2 (en) | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
US20100311767A1 (en) | 2007-02-27 | 2010-12-09 | Abbott Gmbh & Co. Kg | Method for the treatment of amyloidoses |
US8003097B2 (en) | 2007-04-18 | 2011-08-23 | Janssen Alzheimer Immunotherapy | Treatment of cerebral amyloid angiopathy |
JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
ES2684475T3 (es) | 2010-04-15 | 2018-10-03 | Abbvie Inc. | Proteínas que se unen a beta amiloide |
MX358739B (es) | 2010-08-14 | 2018-09-03 | Abbvie Inc Star | Proteinas de union a amiloide beta. |
GB201113570D0 (en) | 2011-08-05 | 2011-09-21 | Glaxosmithkline Biolog Sa | Vaccine |
SI3166970T1 (sl) | 2014-07-10 | 2021-09-30 | Bioarctic Ab | Izboljšana A-beta protofibril vezavna protitelesa |
CN114957438B (zh) * | 2022-06-28 | 2024-04-02 | 福建亿彤生物科技有限公司 | 用于检测阿尔茨海默病的人Aβ1-42抗原决定簇多肽及制法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2081482C (en) * | 1990-04-27 | 2000-11-21 | Ellis L. Kline | Method and composition for treatment of central nervous system disease states associated with abnormal amyloid beta protein molecular organization |
TWI239847B (en) * | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
-
2000
- 2000-05-31 PE PE2000000521A patent/PE20010212A1/es not_active Application Discontinuation
- 2000-05-31 AR ARP000102690A patent/AR024558A1/es unknown
- 2000-06-01 CA CA002374897A patent/CA2374897A1/en not_active Abandoned
- 2000-06-01 WO PCT/US2000/015302 patent/WO2000072870A1/en not_active Application Discontinuation
- 2000-06-01 JP JP2001511317A patent/JP2003519620A/ja not_active Withdrawn
- 2000-06-01 EE EEP200100649A patent/EE200100649A/xx unknown
- 2000-06-01 SK SK1701-2001A patent/SK17012001A3/sk unknown
- 2000-06-01 BR BR0011251-8A patent/BR0011251A/pt not_active Application Discontinuation
- 2000-06-01 NZ NZ515744A patent/NZ515744A/en unknown
- 2000-06-01 RU RU2001135800/14A patent/RU2001135800A/ru unknown
- 2000-06-01 EP EP00942668A patent/EP1181040A1/en not_active Withdrawn
- 2000-06-01 IL IL14657500A patent/IL146575A0/xx unknown
- 2000-06-01 CZ CZ20014150A patent/CZ20014150A3/cs unknown
- 2000-06-01 KR KR1020017015474A patent/KR20020016813A/ko not_active Application Discontinuation
- 2000-06-01 MX MXPA01012355A patent/MXPA01012355A/es unknown
- 2000-06-01 CN CN00808374A patent/CN1353615A/zh active Pending
- 2000-06-01 TR TR2001/03476T patent/TR200103476T2/xx unknown
- 2000-06-01 PL PL00352575A patent/PL352575A1/xx not_active Application Discontinuation
- 2000-06-01 AU AU57261/00A patent/AU5726100A/en not_active Abandoned
-
2001
- 2001-11-26 ZA ZA200109704A patent/ZA200109704B/en unknown
- 2001-11-29 IS IS6182A patent/IS6182A/is unknown
- 2001-11-30 NO NO20015859A patent/NO20015859L/no not_active Application Discontinuation
- 2001-12-04 HR HR20010901A patent/HRP20010901A2/hr not_active Application Discontinuation
- 2001-12-20 BG BG106249A patent/BG106249A/xx unknown
-
2002
- 2002-08-23 HK HK02106241.2A patent/HK1045938A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
NO20015859D0 (no) | 2001-11-30 |
HK1045938A1 (zh) | 2002-12-20 |
AR024558A1 (es) | 2002-10-16 |
TR200103476T2 (tr) | 2002-04-22 |
IL146575A0 (en) | 2002-07-25 |
WO2000072870A1 (en) | 2000-12-07 |
KR20020016813A (ko) | 2002-03-06 |
BG106249A (en) | 2002-08-30 |
EP1181040A1 (en) | 2002-02-27 |
PL352575A1 (en) | 2003-08-25 |
AU5726100A (en) | 2000-12-18 |
CZ20014150A3 (cs) | 2002-05-15 |
EE200100649A (et) | 2003-02-17 |
NZ515744A (en) | 2004-04-30 |
PE20010212A1 (es) | 2001-02-22 |
RU2001135800A (ru) | 2003-08-20 |
BR0011251A (pt) | 2002-03-05 |
IS6182A (is) | 2001-11-29 |
JP2003519620A (ja) | 2003-06-24 |
ZA200109704B (en) | 2003-02-26 |
NO20015859L (no) | 2002-02-01 |
CA2374897A1 (en) | 2000-12-07 |
HRP20010901A2 (en) | 2003-04-30 |
SK17012001A3 (sk) | 2002-06-04 |
CN1353615A (zh) | 2002-06-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MXPA01012355A (es) | Composiciones de peptido a-beta y proceso para producir el mismo. | |
AU2001273094A1 (en) | Compounds to treat alzheimer's disease | |
WO2002002512A3 (en) | Compounds to treat alzheimer's disease | |
AU2001252958A1 (en) | Compounds and methods to treat alzheimer's disease | |
IL189629A0 (en) | Compositions containing human ctla-4 antibodies | |
BG66083B1 (bg) | Фармацевтични състави, съдържащи антитела и антитела за профилактика и лечение на амилоидогенно заболяване | |
GB0108592D0 (en) | Therapeutic agents | |
PL365683A1 (en) | Selected fused pyrrolocarbazoles | |
ATE430193T1 (de) | Rekombinante alpha-l-iduronidase und behandlung von durch diese hervorgerufene mangelerkrankungen | |
WO2001009118A3 (en) | Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement | |
WO2002002520A8 (en) | Compounds to treat alzheimer's disease | |
TW200502221A (en) | Novel lactams and uses thereof | |
RS8504A (en) | Novel cyclohexil sulphones | |
WO2003047507A3 (en) | Factor viii c2 domain variants | |
DE69805305D1 (de) | Verwendung von phanquinon zur behandlung von alzheimer's krankheit | |
ATE464048T1 (de) | Behandlung von alzheimer-krankheit und verwandten zuständen | |
BG102707A (en) | New triazolopurinpurines, method for their preparation and appplication as medicamentous forms | |
TW200504036A (en) | Novel lactams and uses thereof | |
EP1446400A4 (en) | Piperidin derivatives, process for their preparation and pharmaceutical composition for the treatment of Alzheimer's disease containing these derivatives | |
AU2002251788A1 (en) | Novel compounds and uses thereof | |
DE60204818D1 (de) | Zusammensetzungen enthaltend Eisenerz zur topischen Behandlung von bioenergetischen und elektromagnetischen Erkrankungen | |
AU7230894A (en) | Use of efaxoran and its derivatives for the production of drugs for treating neurodegenerative diseases | |
ECSP003504A (es) | Composiciones del peptido a - beta y procesos para producir las mismas | |
DE50006244D1 (en) | Neue substituierte 3-phenoxy- und 3-phenylalkyloxy-2-phenyl-propylamine | |
TR199800850T2 (xx) | Kan� d�zenleyici bile�imler. |